GPCRs are the targets for around one third of all approved drugs 1. Yet such medicines act on only a handful of the 800+ known GPCRs. A wave of biomedical progress in the early 21 st century ...
Heptares was founded in 2007 on this technology, and Nxera is building on this long history and experience to develop the next generation of GPCR-targeted drugs — and beyond. With more than 800 ...
Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...
Septerna, Inc. recently disclosed in an 8-K filing that it will be engaging in discussions at the 43rd Annual J.P. Morgan Healthcare Conference, commencing on January 13, 2025. A corporate ...
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. A mere six months ago Verily ...
Hosted on MSN9d
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter SpikesShares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the ...
Exicure, Inc. (XCUR), a biotechnology company, Thursday announced that it has entered into a share purchase agreement with South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback